title: Helicobacter pylori: treatment with combinations of pivampicillin and tripotassium dicitrato bismuthate.
abstract: Fifty Helicobacter pylori- (H. pylori) positive patients entered an open study and were assigned to one of four treatment regimens comprising: pivampicillin (500 mg b.d.) for 2 weeks +/- tripotassium dicitrato bismuthate (tablet or liquid form) for one month. The 14C-urea breath test was used to evaluate clearance (negative at the end of treatment) and eradication (negative at 1 month post-treatment) of H. pylori. Clearance rates were 20% (2/10) after pivampicillin alone, 86% (12/14) after tripotassium dicitrato bismuthate tablets (240 mg b.d.) plus pivampicillin, 67% (6/9) after tripotassium dicitrato bismuthate tablets (120 mg q.d.s.) plus pivampicillin, and 100% (13/13) after tripotassium dicitrato bismuthate liquid (120 mg in 5 ml q.d.s) plus pivampicillin. The eradication rates were 0% (0/10), 13% (2/15), 0% (0/11) and 54% (7/13), respectively. Combination of the results from the 2 tripotassium dicitrato bismuthate tablet/pivampicillin groups gave an eradication rate of 7.7% (2/26) which was significantly lower than the 53.9% (7/13) obtained with tripotassium dicitrato bismuthate liquid/pivampicillin (P less than 0.02). In conclusion, a liquid tripotassium dicitrato bismuthate pivampicillin combination may be of special use in the treatment of H. pylori-positive patients when triple therapy is contraindicated (e.g. patient sensitivity/allergy to metronidazole) or when the H. pylori isolate is resistant to metronidazole.
authors.affiliation: Department of Medicine, Ipswich Hospital, UK.
authors.forename: J
authors.initials: J
authors.lastname: Weil
authors.forename: G D
authors.initials: GD
authors.lastname: Bell
authors.forename: K
authors.initials: K
authors.lastname: Powell
authors.forename: A
authors.initials: A
authors.lastname: Morden
authors.forename: G
authors.initials: G
authors.lastname: Harrison
authors.forename: P W
authors.initials: PW
authors.lastname: Gant
authors.forename: J E
authors.initials: JE
authors.lastname: Trowell
authors.forename: S
authors.initials: S
authors.lastname: Burridge
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage*; D010917:Pivampicillin / Q000008:administration & dosage*
chemical_list: D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D010917:Pivampicillin; C002791:bismuth tripotassium dicitrate